ClearPoint Neuro, Inc.
CLPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.99 | -0.23 | 8.60 | -0.27 |
| FCF Yield | -2.22% | -8.64% | -8.02% | -5.53% |
| EV / EBITDA | -22.37 | -7.52 | -12.15 | -14.97 |
| Quality | ||||
| ROIC | -67.18% | -62.95% | -33.15% | -21.80% |
| Gross Margin | 60.92% | 56.83% | 65.84% | 68.24% |
| Cash Conversion Ratio | 0.47 | 0.62 | 0.98 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.16% | 13.70% | 17.01% | 2,535,341.84% |
| Free Cash Flow Growth | 36.10% | 12.08% | -27.63% | -55.19% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 0.44 | 1.00 | 3.28 |
| Interest Coverage | 0.00 | 0.00 | -201.63 | -13.75 |
| Efficiency | ||||
| Inventory Turnover | 1.79 | 1.31 | 0.75 | 1.05 |
| Cash Conversion Cycle | 219.12 | 325.45 | 516.89 | 370.44 |